A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Rivaroxaban
- Indications Haemorrhage
- Focus Pharmacodynamics
- Sponsors Portola Pharmaceuticals
- 29 Oct 2019 Status changed from recruiting to completed.
- 04 Feb 2019 Planned number of patients changed from 102 to 108.
- 29 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jan 2020.